Td Asset Management Inc Mirati Therapeutics, Inc. Transaction History

Td Asset Management Inc

$102 Billion
Q2 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$27.8 - $45.35 $3.92 Million - $6.4 Million	141,113 Added 195.7%	213,218 $9.29 Million
Q2 2023 Aug 09, 2023	BUY	$36.13 - $49.49 $169,811 - $232,603	4,700 Added 6.97%	72,105 $2.61 Million
Q1 2023 May 10, 2023	BUY	$36.54 - $54.26 $485,982 - $721,658	13,300 Added 24.58%	67,405 $2.51 Million
Q4 2022 Feb 06, 2023	BUY	$41.27 - $98.62 $947,971 - $2.27 Million	22,970 Added 73.78%	54,105 $2.45 Million
Q2 2022 Aug 04, 2022	SELL	$39.16 - $88.71 $630,476 - $1.43 Million	-16,100 Reduced 34.08%	31,135 $2.09 Million
Q1 2022 May 10, 2022	SELL	$75.82 - $150.97 $1.2 Million - $2.38 Million	-15,796 Reduced 25.06%	47,235 $3.88 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $224,416 - $323,493	1,700 Added 2.77%	63,031 $9.25 Million
Q3 2021 Nov 09, 2021	BUY	$132.13 - $177.45 $540,543 - $725,947	4,091 Added 7.15%	61,331 $10.9 Million
Q2 2021 Aug 11, 2021	BUY	$144.0 - $179.73 $2.91 Million - $3.63 Million	20,186 Added 54.48%	57,240 $9.16 Million
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $271,753 - $378,953	1,710 Added 4.84%	37,054 $6.35 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $1.48 Million - $2.2 Million	9,154 Added 34.95%	35,344 $7.76 Million
Q3 2020 Nov 10, 2020	BUY	$113.26 - $167.27 $113,260 - $167,270	1,000 Added 3.97%	26,190 $4.35 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $180,025 - $300,975	2,500 Added 11.02%	25,190 $2.88 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $403,816 - $672,507	-5,787 Reduced 20.32%	22,690 $1.74 Million
Q4 2019 Feb 11, 2020	SELL	$70.76 - $128.86 $120,292 - $219,062	-1,700 Reduced 5.63%	28,477 $3.67 Million
Q3 2019 Nov 07, 2019	BUY	$77.91 - $109.6 $216,356 - $304,359	2,777 Added 10.14%	30,177 $2.35 Million
Q2 2019 Aug 01, 2019	BUY	$59.49 - $104.71 $464,022 - $816,738	7,800 Added 39.8%	27,400 $2.82 Million
Q1 2019 May 08, 2019	BUY	$43.65 - $78.95 $165,870 - $300,010	3,800 Added 24.05%	19,600 $1.44 Million
Q4 2018 Feb 01, 2019	BUY	$32.0 - $47.43 $9,600 - $14,229	300 Added 1.94%	15,800 $670,000
Q3 2018 Nov 01, 2018	BUY	$47.1 - $62.7 $343,830 - $457,710	7,300 Added 89.02%	15,500 $730,000
Q2 2018 Jul 31, 2018	BUY	$26.05 - $52.4 $5,210 - $10,480	200 Added 2.5%	8,200 $404,000
Q1 2018 May 11, 2018	BUY	$17.2 - $34.95 $137,600 - $279,600	8,000 New	8,000 $246,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account